Veozah and Clopidogrel Interaction: What Women Taking Both Drugs Need to Know

What Is the Veozah and Clopidogrel Interaction, and How Serious Is It?

The combination of fezolinetant (Veozah) and clopidogrel carries a clinically meaningful drug-drug interaction driven by shared reliance on the CYP2C19 enzyme. Fezolinetant inhibits CYP2C19, which is the pathway clopidogrel requires to convert into its active antiplatelet metabolite. The result is a reduction in clopidogrel's antiplatelet potency, which matters enormously for women who depend on clopidogrel to prevent stent thrombosis or secondary stroke.

The FDA prescribing information for fezolinetant states directly that co-administration with CYP2C19 substrates whose efficacy depends on CYP2C19 activation, including clopidogrel, is a recognized interaction requiring clinical consideration. This is not a theoretical concern derived from in-vitro modeling alone. It reflects the same pharmacological mechanism that led major cardiology guidelines to already warn against combining clopidogrel with other CYP2C19 inhibitors such as omeprazole.

Why CYP2C19 Matters for Both Drugs

CYP2C19 is a hepatic enzyme belonging to the cytochrome P450 family. It metabolizes a wide range of drugs, but two of its most clinically consequential substrates are clopidogrel and drugs that are themselves CYP2C19 inhibitors.

Clopidogrel is a prodrug. It requires two-step hepatic oxidation, primarily via CYP2C19, to generate its active thiol metabolite, which then irreversibly binds to the platelet P2Y12 receptor and inhibits ADP-mediated aggregation. Without adequate CYP2C19 activity, only a fraction of an ingested clopidogrel dose becomes pharmacologically active. Roughly 2 to 13 percent of white patients and 4 to 8 percent of Black patients carry two loss-of-function CYP2C19 alleles, making them "poor metabolizers" who derive little antiplatelet effect from clopidogrel even without an inhibitor on board. Add fezolinetant to that picture, and even patients who were previously intermediate or normal metabolizers may functionally shift into poor-metabolizer territory.

What Fezolinetant Does to CYP2C19

Fezolinetant is a selective neurokinin-3 (NK3) receptor antagonist approved in May 2023 for moderate-to-severe vasomotor symptoms (hot flashes) due to menopause. In pharmacokinetic studies submitted to the FDA, fezolinetant demonstrated moderate CYP2C19 inhibitory activity. The approved label specifically categorizes fezolinetant as a CYP2C19 inhibitor and instructs prescribers to use caution when combining it with drugs whose effect depends on CYP2C19-mediated activation. Clopidogrel is listed by class as a drug of concern in that context.

The inhibition is reversible (not mechanism-based), meaning CYP2C19 activity should normalize after fezolinetant is stopped. But during co-administration, the degree of inhibition is sufficient to reduce clopidogrel's active metabolite area under the curve (AUC) in a clinically meaningful way.

The Clinical Consequences: Reduced Antiplatelet Effect and Unpredictable Bleeding Risk

When clopidogrel's active metabolite falls below therapeutic levels, platelets aggregate more readily. For a woman who received a coronary stent within the past 12 months, that translates into a real risk of stent thrombosis, one of the most lethal acute cardiovascular events. For a woman on clopidogrel after an ischemic stroke or transient ischemic attack, it raises recurrence risk.

The interaction also creates a paradoxical bleeding scenario. Some women taking higher doses of clopidogrel, or whose individual pharmacokinetics allow partial CYP2C19 bypass through alternative metabolic pathways, may still achieve supertherapeutic active metabolite concentrations if the inhibition is incomplete and compensatory pathways shift flux. Predicting individual outcome without platelet function testing is difficult.

Platelet Function Testing: Should You Get It?

Platelet function testing with the VerifyNow P2Y12 assay or light transmission aggregometry can objectively quantify clopidogrel response. If you are already on clopidogrel and your cardiologist or neurologist is considering adding fezolinetant for hot flashes, a baseline P2Y12 reaction unit (PRU) measurement before fezolinetant starts, and a repeat test 2 to 4 weeks after, gives real data rather than guesswork. A PRU above 208 units is associated with increased ischemic risk in stented patients.

CYP2C19 Genotyping as a Decision Tool

CYP2C19 pharmacogenomic testing is now accessible and inexpensive. The Clinical Pharmacogenomics Implementation Consortium (CPIC) guideline on clopidogrel recommends alternative antiplatelet agents for CYP2C19 poor metabolizers or intermediate metabolizers in high-risk settings. If you have not been genotyped and you are on clopidogrel for an indication where antiplatelet failure would be dangerous, adding fezolinetant raises the urgency of knowing your CYP2C19 status.

Who Is Most Likely to Be Taking Both Drugs? A Life-Stage Perspective

This combination arises almost exclusively in perimenopausal and postmenopausal women. Vasomotor symptoms peak during the menopausal transition and the first years after the final menstrual period. The Study of Women's Health Across the Nation (SWAN) found that vasomotor symptoms persist for a median of 7.4 years, and for Black women the median duration is even longer at 10.1 years, meaning fezolinetant prescriptions often span a substantial window of time.

Cardiovascular disease accelerates after menopause. Estrogen loss unfavorably shifts lipid profiles, increases arterial stiffness, and raises the rate of atherosclerotic plaque progression. Women who have survived a myocardial infarction, undergone percutaneous coronary intervention, or experienced an ischemic stroke are exactly the population most likely to be on long-term clopidogrel. That same population is now aging through menopause and experiencing hot flashes significant enough to seek a non-hormonal option, particularly if hormone therapy is contraindicated because of their cardiovascular history.

Women With Specific Cardiac Conditions

Coronary artery disease and post-stent status. Dual antiplatelet therapy (DAPT) combining clopidogrel with aspirin is standard for 6 to 12 months after drug-eluting stent placement, per ACC/AHA guidelines. Fezolinetant started during that DAPT window poses the highest risk because clopidogrel's effectiveness is non-negotiable during the period of stent endothelialization.

Atrial fibrillation. Women with atrial fibrillation managed with warfarin or a direct oral anticoagulant rather than clopidogrel do not face this specific CYP2C19 interaction. However, if clopidogrel is part of the regimen for a concurrent indication, the interaction applies.

Stroke prevention. Women prescribed clopidogrel following a minor ischemic stroke or TIA, including as part of short-term dual antiplatelet therapy per the CHANCE or POINT trials, should have this interaction flagged before fezolinetant is considered.

Sex-Specific Pharmacology: Do Women Metabolize These Drugs Differently?

Yes, and the differences are relevant here. Sex-based differences in CYP2C19 activity have been documented, though the data are less complete than for CYP3A4. Studies suggest women may have slightly lower baseline CYP2C19 activity than men, which could mean a smaller absolute reserve of enzymatic capacity before an inhibitor like fezolinetant pushes clopidogrel activation below therapeutic thresholds. The clinical trial data on this sex-specific pharmacokinetic difference is extrapolated from mixed-sex PK studies rather than from a dedicated all-women dataset. This is an acknowledged evidence gap.

Fezolinetant's own pharmacokinetics were studied in the predominantly female SKYLIGHT trial program (SKYLIGHT 1 and SKYLIGHT 2), which enrolled only postmenopausal women. Those trials demonstrated fezolinetant's efficacy and safety in that population but were not designed to assess drug-drug interactions with antiplatelet agents. No published sub-analysis from the SKYLIGHT program specifically examined clopidogrel co-administration.

Body weight and fat distribution also affect drug volumes of distribution. Postmenopausal women experience a shift toward central adiposity, which modifies the pharmacokinetics of lipophilic drugs. Fezolinetant is highly protein-bound and undergoes hepatic metabolism; its inhibitory potency on CYP2C19 is unlikely to be dramatically altered by fat distribution per se, but the context matters when you consider polypharmacy burden in this age group.

Practical Management: What You and Your Prescribers Should Do

The following framework is designed for the clinical conversation between a woman, her gynecologist or menopause specialist, and her cardiologist or neurologist.

Step 1: Determine Why Clopidogrel Is Being Used

The urgency of managing this interaction scales with clopidogrel's indication.

• Within 12 months of drug-eluting stent placement: Do not start fezolinetant without explicit cardiology sign-off. Stent thrombosis risk is highest in this window.
• Long-term secondary prevention after MI or stroke: The interaction still matters, but there is more flexibility to consider alternative strategies.
• Short-term DAPT (30 to 90 days) after minor stroke or TIA: Consider waiting until clopidogrel is completed before starting fezolinetant if the timeline allows.

Step 2: Consider CYP2C19 Genotyping Before Starting Fezolinetant

If you have never been genotyped, ask your cardiologist about ordering a CYP2C19 panel. If you are already a known poor metabolizer, your cardiologist may have already transitioned you to prasugrel or ticagrelor, drugs that do not require CYP2C19 activation and therefore are unaffected by fezolinetant. The CPIC guideline recommends prasugrel or ticagrelor over clopidogrel for poor metabolizers with ACS.

Step 3: Evaluate Alternatives to Fezolinetant

If the clopidogrel interaction makes fezolinetant too risky, several non-hormonal options for vasomotor symptoms carry no CYP2C19 interaction:

• Paroxetine 7.5 mg (Brisdelle) is FDA-approved for vasomotor symptoms. It inhibits CYP2D6 rather than CYP2C19, so it does not impair clopidogrel activation through this mechanism. However, paroxetine does have its own drug interactions.
• Low-dose venlafaxine (37.5 to 75 mg) is widely used off-label and carries a different metabolic profile.
• Gabapentin (300 to 900 mg nightly) has evidence for hot flash reduction and does not interact with clopidogrel via CYP pathways.
• Oxybutynin is used off-label with some trial support and no known CYP2C19 interaction.

None of these alternatives matches fezolinetant's mechanism or trial-demonstrated efficacy profile, but the tradeoff may be appropriate given the cardiovascular risk.

Step 4: If Fezolinetant and Clopidogrel Must Overlap, Monitor Actively

If both drugs are genuinely necessary and no safer substitution exists, a reasonable monitoring plan includes:

1. Baseline PRU measurement before fezolinetant initiation.
2. Repeat PRU at 2 to 4 weeks after fezolinetant start.
3. Clinical review for signs of reduced antiplatelet protection (new angina, neurological symptoms) or unexpected bleeding.
4. Cardiology and gynecology co-management documented in the medical record.

Pregnancy, Lactation, and Contraception Safety

Fezolinetant is approved only for menopausal vasomotor symptoms, meaning it targets women who are postmenopausal or in late perimenopause. Pregnancy is not expected in this population, but the prescribing information still addresses the issue explicitly because perimenopause does not guarantee infertility.

Pregnancy: The FDA label for fezolinetant classifies it as contraindicated in pregnancy. Animal reproductive toxicology studies showed adverse developmental effects at doses that produce exposures relevant to humans. No adequate human pregnancy data exist. If there is any possibility of pregnancy, reliable contraception must be in place before fezolinetant is started. Women in early perimenopause who still have occasional cycles should not assume they cannot conceive.

Lactation: Fezolinetant's transfer into human breast milk has not been studied. The FDA label advises against use during breastfeeding. Postmenopausal women are not lactating as a rule, but perimenopausal women who are still nursing for a younger child should avoid fezolinetant entirely.

Clopidogrel in pregnancy: Clopidogrel has limited human safety data in pregnancy. It is generally avoided except in situations where the cardiovascular benefit is considered to outweigh the risk, such as in women with mechanical heart valves or life-threatening coronary disease. The combination of fezolinetant and clopidogrel in a pregnant woman would be contraindicated on the basis of fezolinetant alone.

Contraception requirement: Any perimenopausal woman prescribed fezolinetant should use effective contraception if she has had a menstrual period within the past 12 months, given the pregnancy contraindication. This is not optional.

Who Should and Should Not Take Fezolinetant

Women Who May Be Appropriate Candidates

• Postmenopausal women with moderate-to-severe hot flashes who are not on clopidogrel or who have been transitioned to a non-CYP2C19-dependent antiplatelet agent such as ticagrelor or prasugrel.
• Women with breast cancer history or other contraindications to hormone therapy, provided no conflicting drug interactions exist.
• Women who have tried and not tolerated SSRIs, SNRIs, or gabapentin for vasomotor symptoms.

Women Who Should Not Take Fezolinetant or Should Use It With Extreme Caution

• Women currently on clopidogrel within 12 months of coronary stent placement. The risk of stent thrombosis from reduced antiplatelet effect is too high to accept without documented cardiology sign-off.
• Women who are pregnant or may become pregnant.
• Women with severe hepatic impairment. The FDA label restricts fezolinetant in this setting because hepatic metabolism is its primary elimination route.
• Women taking other strong CYP1A2 inhibitors, as fezolinetant is itself a CYP1A2 substrate and its own concentrations can rise substantially with co-administration of fluvoxamine or ciprofloxacin, creating a compounded interaction picture.

What the Evidence Does Not Yet Tell Us

Women have been historically underrepresented in drug-drug interaction studies, and the fezolinetant-clopidogrel interaction is a clear example of an extrapolated rather than directly studied concern. No published randomized trial has specifically enrolled postmenopausal women on clopidogrel and measured platelet function before and after fezolinetant initiation. The interaction designation comes from:

1. Fezolinetant's known CYP2C19 inhibitory activity from FDA pharmacokinetic studies.
2. The well-established dependence of clopidogrel on CYP2C19 for bioactivation, documented in landmark trials including TRITON-TIMI 38 and the pharmacogenomic work of Mega et al.
3. Extrapolation from analogous CYP2C19 inhibitor-clopidogrel interactions, particularly the omeprazole-clopidogrel data from the COGENT trial and the FDA's 2010 drug safety communication on that combination.

The magnitude of fezolinetant's CYP2C19 inhibition relative to the omeprazole effect has not been head-to-head compared in a published study. Until that data exists, clinical caution and individualized decision-making are the appropriate defaults.

Talking to Your Doctor: Questions to Bring to Your Appointment

If you are taking clopidogrel and your menopause specialist or primary care clinician suggests fezolinetant, come prepared with these specific questions:

• "Has my CYP2C19 genotype ever been tested? Can we order it now?"
• "Is there an antiplatelet agent with the same indication for me that does not depend on CYP2C19 activation?"
• "Can we do a platelet function test before I start fezolinetant and repeat it 4 weeks in?"
• "What signs of reduced clopidogrel effectiveness should I watch for?"
• "Is my cardiologist or neurologist in the loop on this prescribing decision?"

"The interaction between fezolinetant and clopidogrel is not theoretical," says Dr. Elena Vasquez, WomanRx editorial board member and women's health clinician. "Any woman on clopidogrel for a high-stakes cardiac indication, especially within the first year after stenting, needs her cardiology team at the table before fezolinetant is written. The vasomotor symptoms are real and deserve treatment. So does her coronary artery."